NASDAQ:ARAY - Accuray Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.88 -0.03 (-0.77 %)
(As of 12/13/2018 01:39 AM ET)
Previous Close$3.91
Today's Range$3.87 - $4.0150
52-Week Range$3.20 - $6.15
Volume503,296 shs
Average Volume734,945 shs
Market Capitalization$333.64 million
P/E Ratio-13.86
Dividend YieldN/A
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:ARAY
Previous Symbol


Debt-to-Equity Ratio2.74
Current Ratio1.69
Quick Ratio0.96


Trailing P/E Ratio-13.86
Forward P/E Ratio-27.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$404.90 million
Price / Sales0.83
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.57 per share
Price / Book6.81


EPS (Most Recent Fiscal Year)($0.28)
Net Income$-23,890,000.00
Net Margins-5.79%
Return on Equity-42.24%
Return on Assets-5.17%


Outstanding Shares86,660,000
Market Cap$333.64 million

Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings data on Tuesday, October, 30th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.02. The medical equipment provider had revenue of $95.83 million for the quarter, compared to analysts' expectations of $95.10 million. Accuray had a negative return on equity of 42.24% and a negative net margin of 5.79%. During the same period in the previous year, the business posted ($0.11) earnings per share. View Accuray's Earnings History.

When is Accuray's next earnings date?

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Accuray.

What price target have analysts set for ARAY?

5 analysts have issued twelve-month price objectives for Accuray's stock. Their forecasts range from $3.90 to $6.00. On average, they anticipate Accuray's stock price to reach $5.4750 in the next twelve months. This suggests a possible upside of 41.1% from the stock's current price. View Analyst Price Targets for Accuray.

What is the consensus analysts' recommendation for Accuray?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.

What are Wall Street analysts saying about Accuray stock?

Here are some recent quotes from research analysts about Accuray stock:
  • 1. BTIG Research analysts commented, "While we were out sick, Accuray posted a ~$6M revenue beat but missed gross order expectations. Although the company fell short of its guided 5% y/y growth in gross orders for FY18, we liked the sales step up, strong revenue guidance for FY19, and the increasing funnel of anticipated multi- system orders. The company’s decision to move away from annual gross order guidance may bother some but is probably the correct move given mgmt’s inability to consistently accurately predict this. Pinning down an order growth rate is likely to become more challenging, as we expect more multi-system orders to add timing unpredictability and more lumpiness to quarterly numbers. Overall, while it may be tougher – at least near term – to get visibility into quarterly orders, we see larger multi-unit bookings as a win for ARAY." (8/22/2018)
  • 2. According to Zacks Investment Research, "Accuray successfully rides on the market’s solid response to the Radixact platform. Recently, the Radixact X9 received the AERB approval for its sale in India. Growing adoption of non-surgical treatment options, successful execution of restructuring plans and accretive acquisitions are other positives. A series of software upgradation has been another growth driver. These upgrades include integrated data management system (IDMS) and Accuray Precision Treatment Planning Software. On the flip side, the company lowered the EBITDA expectations largely due to strategic investments and lower-than-expected gross margins. Long sales and implementation cycle of the CyberKnife and TomoTherapy systems is a headwind, keeping margins under pressure. Furthermore, unfavorable product mix, declining service revenues, sluggish macro-economic conditions and pricing headwinds are major concerns. Accuray has underperformed the industry in the past three months." (7/3/2018)

Has Accuray been receiving favorable news coverage?

Headlines about ARAY stock have been trending very positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accuray earned a media sentiment score of 3.6 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Accuray's key competitors?

Who are Accuray's key executives?

Accuray's management team includes the folowing people:
  • Mr. Joshua H. Levine, Pres, CEO & Director (Age 60)
  • Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 55)
  • Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 59)
  • Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 45)
  • Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.86%), Vanguard Group Inc. (7.06%), Renaissance Technologies LLC (6.13%), Neuberger Berman Group LLC (4.97%), Russell Investments Group Ltd. (4.62%) and Partner Fund Management L.P. (4.53%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Kelly Londy, Kevin Waters and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.

Which institutional investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Vanguard Group Inc., Alambic Investment Management L.P., Morgan Stanley, BlackRock Inc., Russell Investments Group Ltd., Neuberger Berman Group LLC and Credit Suisse AG. Company insiders that have sold Accuray company stock in the last year include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Kevin Waters and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.

Which institutional investors are buying Accuray stock?

ARAY stock was acquired by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., Marshall Wace LLP, Renaissance Technologies LLC, Assenagon Asset Management S.A., JPMorgan Chase & Co., JPMorgan Chase & Co., Putnam Investments LLC and Heartland Advisors Inc.. View Insider Buying and Selling for Accuray.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $3.88.

How big of a company is Accuray?

Accuray has a market capitalization of $333.64 million and generates $404.90 million in revenue each year. The medical equipment provider earns $-23,890,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Accuray employs 998 workers across the globe.

What is Accuray's official website?

The official website for Accuray is

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]

MarketBeat Community Rating for Accuray (NASDAQ ARAY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel